NOVUS THERAPEUTICS INC's ticker is NVUS and the CUSIP is 67011N105. A total of 21 filers reported holding NOVUS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $2,000 | -71.4% | 4,067 | -65.5% | 0.00% | – |
| Q3 2019 | $7,000 | -82.5% | 11,773 | -70.9% | 0.00% | – |
| Q2 2019 | $40,000 | -45.2% | 40,452 | +120.6% | 0.00% | – |
| Q1 2019 | $73,000 | -9.9% | 18,338 | -63.9% | 0.00% | – |
| Q4 2018 | $81,000 | -88.1% | 50,846 | -65.1% | 0.00% | – |
| Q3 2018 | $680,000 | +10.7% | 145,801 | +66.1% | 0.00% | – |
| Q2 2018 | $614,000 | +3511.8% | 87,799 | +2375.3% | 0.00% | – |
| Q1 2018 | $17,000 | – | 3,547 | +88575.0% | 0.00% | – |
| Q4 2017 | $0 | -100.0% | 4 | -98.7% | 0.00% | – |
| Q3 2017 | $1,000 | -94.4% | 315 | -90.4% | 0.00% | – |
| Q2 2017 | $18,000 | – | 3,276 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 3,183,314 | $54,435,000 | 0.68% |
| Asymmetry Capital Management, L.P. | 1,088,907 | $1,034,000 | 0.66% |
| BVF INC/IL | 3,515,873 | $3,340,000 | 0.18% |
| Renaissance Technologies | 758,149 | $720,000 | 0.00% |
| ACADIAN ASSET MANAGEMENT LLC | 170,176 | $162,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 20,282 | $19,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 11,000 | $10,000 | 0.00% |
| ROYAL BANK OF CANADA | 1 | $0 | 0.00% |
| UBS Group AG | 4,200 | $4,000 | 0.00% |
| THRIVENT FINANCIAL FOR LUTHERANS | 45,761 | $43,000 | 0.00% |